ESPR
Esperion Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.18
+0.00%Price chart
Jun 11Jun 16Jun 22Jun 25Jun 30Jul 6Jul 9Jul 14
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
30.3x
Market Cap
$819.46M
MomentumView details →
1D Return
+0.00%
YTD Return
−14.05%
RSI (14)
64.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
30.3x
Market Cap
$819.46M
RSI (14)
64.5
MomentumView details →
1D Return
+0.00%
YTD Return
−14.05%
SummaryUpdated Mar 1, 2026
Esperion Therapeutics, Inc. (NASDAQ:ESPR) is a pharmaceutical company founded in 2008 and headquartered in Ann Arbor, Michigan. The company went public in 2013 and focuses on developing and commercializing medicines for patients with elevated low-density lipoprotein (LDL) cholesterol, commonly known as "bad cholesterol." Esperion has successfully brought two cholesterol-lowering drugs to market and continues expanding its pipeline while building international partnerships to grow its global footprint.
Similar companies
Latest newsMore news →